AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05878691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 54276 + Atezolizumab
Description: Part 1b: GRC 54276 QD will be administered orally in combination with fixed dose of atezolizumab IV every 21 days.~Part 2: GRC 54276 in combination with atezolizumab will commence after establishment of the MTD and/or RP2D for combination therapy arm.
Study NCT04587960 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed primary closure of skin incision in Caesarean section in experimental group
Description: Delayed closure of skin wound of emergency Caesarean section following wound dressing for 2-3 days in experimental group
Study NCT04587960 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary closure of skin incision in Caesarean section in active comparator group
Description: Primary closure of skin wound (incisional) at the time of emergency Caesarean section in active comparator group
Study NCT04919772 — intervention group
Intervention type: OTHER
Intervention: Assessment
Description: The participants walk 4-meter and 10-meter and 5-repetition sit-to-stand twice.
Study NCT06013319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The load dose of esmolol was first injected intravenously: 0.5mg/kg.min, for about 1 minute; then the maintenance dose was pumped intravenously: from 0.05mg/kg/min, and continued after 4 minutes if the efficacy was ideal; if the efficacy was poor, the load dose could be repeated and the maintenance dose increased by 0.05mg/kg/min. The maintenance dose should not exceed 0.3mg/kg/min.
Study NCT04853277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Each Patient will undergo a 30 minute telephone visit with a trained Medical Provider outlining the timeline of various common emotional challenges experienced after transplant/CAR-T, as well as coping techniques. A pamphlet with information discussed will also be provided to the patient to review on their own time. The patient will have an opportunity to express any psychosocial/emotional concerns at this time.
Study NCT05265962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine plus Penpulimab
Description: Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
Study NCT05227768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 25mg Group
Description: 4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
Study NCT05227768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 200mg Group
Description: 6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
Study NCT05227768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 400mg Group
Description: 6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
Study NCT05227768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 800mg Group
Description: 6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
Study NCT05227768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 1200mg Group
Description: 6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
Study NCT05386849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FUSION closed loop glucose control system
Description: The FUSION system will be used to control the subjects glucose to a range of 100-140 mg/dL. Data will be collected for up to 24 hours, or upon early termination of the study session.
Study NCT05166551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: This study will be conducted in a randomized placebo-controlled research design to investigate the effect of acupressure, to be applied to the Gall Bladder (GB) 31 Fengshi acupuncture point before the vaccinations, on interventional pain in infants (0-1 years) caused by the vaccine.
Study NCT05166551 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupressure
Description: Placebo Acupressure
Study NCT04770181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Stim AID CES (Active Comparator)
Description: The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
Study NCT04770181 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim AID CES (Sham Comparator)
Description: The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
Study NCT06791902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive DBS
Description: Adapting DBS stimulation based on locomotor states
Study NCT06789744 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (GA)
Description: Patients will be induced with general anesthesia, consisting of propofol (1.5-2 mg/kg intravenously), rocuronium (1-2 mg/kg intravenously), and fentanyl (1-2 μg/kg intravenously). Anesthesia will be maintained with inhaled sevoflurane or desflurane, adjusted according to BIS values. Remifentanil (0.05-0.2 μg/kg/min) will be administered via continuous infusion, with the infusion rate adjusted to maintain blood pressure and heart rate within ±20% of baseline.~Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode using an Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA). Ventilator settings will be as follows: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and inspired oxygen concentration of 41%.
Study NCT06789744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Description: Patients will be induced with general anesthesia, consisting of propofol (1.5-2 mg/kg intravenously), rocuronium (1-2 mg/kg intravenously), and fentanyl (1-2 μg/kg intravenously). Anesthesia will be maintained with inhaled sevoflurane or desflurane, adjusted according to BIS values. Remifentanil (0.05-0.2 μg/kg/min) will be administered via continuous infusion, with the infusion rate adjusted to maintain blood pressure and heart rate within ±20% of baseline.~Following induction, patients will be mechanically ventilated in pressure-regulated volume control (PRVC) mode using an Aestiva anesthesia machine (GE Healthcare, Waukesha, Wisconsin, USA). Ventilator settings will be as follows: tidal volume 6-8 mL/kg, positive end-expiratory pressure 0 cmH2O, inspiratory-to-expiratory ratio 1:2, respiratory rate 16 breaths per minute (BPM), and inspired oxygen concentration of 41%.
Study NCT06789744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia( 0.2% ropivacaine)
Description: For epidural analgesia, an initial bolus of 5-15 mL of 0.5% ropivacaine will be administered, followed by a continuous infusion of 0.2% ropivacaine at a rate of 3-10 mL/hour. In pediatric patients, the initial bolus will consist of 0.2% ropivacaine at a dose of 0.5-1 mg/kg, not to exceed 2-2.5 mg/kg, followed by a continuous infusion of 0.1-0.3 mg/kg/hour.
Study NCT06789744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paravertebral block ( liposomal bupivacaine 133 mg or 0.2% ropivacaine)
Description: For paravertebral blocks, patients will be positioned either sitting or in the lateral decubitus position to fully expose the target area of the spine. The spinous process of the target vertebra will be palpated, and the puncture site identified. Using ultrasound guidance, the paravertebral space will be located. After standard skin preparation, a blunt needle will be advanced perpendicular to the skin. Once the needle tip contacts the transverse process, it will be withdrawn 1-2 mm, and then slightly angled caudally to pass through the paravertebral ligament and enter the paravertebral space. After negative aspiration for blood or cerebrospinal fluid, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 5 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
Study NCT06789744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transversus Abdominis Plane Block (TAP Block)( liposomal bupivacaine 133 mg or 0.2% ropivacaine)
Description: For TAP blocks, patients will be positioned supine with the abdomen exposed. Following standard skin preparation, a needle will be advanced perpendicular to the skin using ultrasound guidance, through the external oblique and internal oblique muscles to reach the fascial plane between the transversus abdominis and internal oblique muscles. After negative aspiration for blood, a 5 mL test dose of local anesthetic will be slowly injected, and the patient observed for adverse effects. If none are noted, an additional 10 mL of local anesthetic will be injected. The local anesthetic solution will be either liposomal bupivacaine (266 mg diluted to 20 mL) or 0.2% ropivacaine.
Study NCT06789744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal Morphine
Description: For intrathecal analgesia, adults will receive 0.1-0.2 mg of morphine intrathecally. For pediatric patients, the dose of intrathecal morphine will be 5-10 mcg/kg.
Study NCT06789744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Patient-Controlled Analgesia (PCA) (fentanyl)
Description: For intravenous PCA, a solution of fentanyl 2 mcg/kg will be diluted to a total volume of 100 mL with normal saline. The PCA settings will be as follows: a basal rate of 2 mL/hour, a PCA dose of 2 mL, and a lockout interval of 15 minutes.
Study NCT06792292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional colonoscopy procedure
Description: Study subjects in this interventional arm will undergo conventional colonoscopy.
Study NCT06792292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: artificial intelligence-assisted colonoscopy procedure
Description: Study subjects in this interventional arm will undergo colonoscopy done with a commercially-available module that uses artificial intelligence to highlight suspected polyps on the screen during colonoscopy. This module also attempts to characterize the detected polyp as adenomatous or not. The detection and characterization of polyps is in real time, during the procedure.
Study NCT06790576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed-loop-peak
Description: With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-peak (each pulse synchronized to person's peak of theta waveform)
Study NCT06790576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open-loop
Description: With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: open-loop (TMS pulse delivered without regard to EEG)
Study NCT06790576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: closed-loop-trough
Description: With single pulse TMS stimulation at F3 based on 10-20 EEG system, TMS evoked potentials (TEPs) will be collected under three TMS synchronization conditions: closed-loop-trough (each pulse synchronized to trough of theta waveform)
Study NCT06792227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT-H
Description: FBT is a structured treatment lasting 6-12 months, typically in an outpatient setting, with weekly sessions that gradually decrease in frequency over time (Lock \& Le Grange, 2015). It empowers parents to manage their child's recovery from the ED. The first phase focuses on weight restoration, with parents responsible for all eating decisions and restricting physical activity to reduce ED's influence. In the second phase, eating responsibility gradually shifts back to the adolescent. The final phase supports healthy adolescent development as ED symptoms subside.~The FBT-H adapts FBT to a home setting, with treatment led by family counselors and psychologists as part of a multidisciplinary team, including therapists, psychologists, a psychiatrist and a nurse specialist.
Study NCT06792526 — intervention group
Intervention type: OTHER
Intervention: IVIM Imaging MRF Imaging
Description: IVIM imaging will be performed to evaluate microstructural and perfusion changes in the salivary glands of Head and Neck Cancer undergoing radiotherapy. This technique quantifies diffusion and perfusion parameters, providing insights into early tissue damage. MRF imaging will be used to quantify salivary gland tissue characteristics, including relaxation parameters (T1 and T2 mapping), to monitor radiotherapy-induced damage. The technique enables precise tissue characterization through multi-parametric MRI.
Study NCT06790654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message based motivational interviewing
Description: Participants will receive weekly text messages during the pilot study period, initiated and managed by MItrained interviewers. Each text message exchange will begin with a short, MI-consistent prompt developed with input from focus groups of mothers who have previously breastfed. These prompts will address common breastfeeding barriers. Following the initial prompt, MI-trained trainers will engage with participants through text exchanges that utilize the core MI OARS skills (open-ended questions, affirmations, reflections, or summaries) to facilitate change talk.
Study NCT06792487 — intervention group
Intervention type: PROCEDURE
Intervention: skin biopsy
Description: punch biopsy (6 mm) of lesional psoriasis skin
Study NCT05026255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alveolar recruitment manoeuvre by pressure step
Description: The application of alveolar recruitment manoeuvres consists of transiently increasing alveolar pressure in order to re-open collapsed alveolar territories and to re-ventilate poorly ventilated or non-ventilated lung areas.
Study NCT06053996 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hepatopulmonary radio-sterilization
Description: Hepatopulmonary radio-sterilization - ablation of hepatic and pulmonary metastases
Study NCT04510584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.
Study NCT04510584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a recombinant humanized IgG1 monoclonal antibody that binds VEGF, a secreted factor that stimulates angiogenesis. Bevacizumab prevents the interaction of VEGF with its receptors and neutralizes the biological activity of VEGF.
Study NCT06791733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive static stretching
Description: the intervention consists of passive static stretching of agonist or antagonist muscles between sets
Study NCT06792110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Integrated Hearing Aid Use
Description: Participants in this arm will use the study-designed artificial intelligence-integrated hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
Study NCT06792110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Infineo Hearing Aid
Description: Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
Study NCT06792110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oticon Real Hearing Aid
Description: Participants in this arm will use a fitted commercial hearing aid in the listening tasks. Participants will also perform the listening tasks without hearing aids to act as controls.
Study NCT06783946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: The meditation technique will be comprised of breathing techniques, full body relaxation, color meditation, visualization, and positive affirmations. A physician researcher trained in teaching meditation will conduct virtual meditation sessions with patients enrolled in the study. Participants will practice a daily 20-minute meditation for 2-4 weeks before scheduled surgery (whichever is the maximum length of time from enrollment) to 2 weeks post-operatively using the provided audio guided meditation recordings. Participants will also log completion of daily meditation practice electronically.
Study NCT06790329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty with fundal mucosal ablation
Description: Mucosal ablation around the gastric fundus is initially performed using a hybrid argon plasma coagulation (H-APC) probe, following a submucosal saline injection, until ablation coagulum is visible. Subsequently, endoscopic sleeve gastroplasty (ESG) is performed using a full-thickness endoscopic suturing device (Overstitch, Apollo). This is done in a standard manner, employing 6-8 permanent full-thickness sutures along the greater curvature of the stomach in a running plication, starting from the angular incisura and extending proximally while sparing the fundus. Hemostasis is carefully checked and confirmed before the procedure is completed.
Study NCT06791629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation
Description: Patients will be treated with pulsed field ablation for atrial fibrillation.
Study NCT06791629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Patients will be treated with radiofrequency ablation for atrial fibrillation.
Study NCT06792058 — intervention group
Intervention type: DEVICE
Intervention: Mechanomiograph: The gold standard of quantitative monitoring
Description: The gold standard of quantitative monitoring is mechanomyography (MMG), which measures the force of contraction of the adductor pollicis muscle following ulnar nerve stimulation. MMG responses are accurate and reproducible. However, the complex and bulky devices are only suitable for research use, are not suitable for clinical use and are not commercially available.
Study NCT06792058 — intervention group
Intervention type: DEVICE
Intervention: Electromiograph
Description: Another type of monitor is the electromyograph, which can be seen as an alternative to mechanomyography because of its accuracy. This technique measures muscle activity as a summation of the action potentials of muscle fibres. This activity is proportional to the strength of the muscle contraction. The most commonly innervated nerve is also the ulnar nerve, which innervates the abductor digiti minimi and the first dorsalis interosseus muscles. During the measurements, electrical signals from these muscles are detected. EMG has several advantages over other monitoring techniques. It does not require immobilisation of the hand, thumb immobility is not a problem, no preload is required, and hypothermia does not affect the hand as much as other neuromuscular monitors. The TetraGraph (Senzime AB, Sweden) is a portable EMG-based neuromuscular minitor for which the manufacturers received marketing approval from the U.S. Food and Drug Administration (FDA) in 2019.
Study NCT06792149 — intervention group
Intervention type: PROCEDURE
Intervention: surgical resection
Description: Surgical resection will be performed for locoregional lesions .
Study NCT06792149 — intervention group
Intervention type: OTHER
Intervention: Adjuvant chemotherapy
Description: Regimens of adjuvant chemotherapy are directed by clinical guidance and experience.
Study NCT06792149 — intervention group
Intervention type: OTHER
Intervention: neoadjuvant therapy
Description: Regimens of neoadjuvant chemotherapy are directed by clinicalguidance and experience
Study NCT06791070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with Toripalimab
Description: Disitamab Vedotin at a dosage of 2mg/kg and 3mg/kg of Toripalimab administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Study NCT06791915 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation with FCV.
Description: Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Flow Controlled Mechanical Ventilation (FCV).
Study NCT06791915 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency Ablation with VCV.
Description: Treatment of atrial fibrillation patients with radiofrequency ablation under general anesthesia with Volume Controlled Mechanical Ventilation (VCV).
Study NCT06369285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets will be taken by mouth twice daily on days 1-3, 8-10, and 15-17 of each 28-day cycle.
Study NCT06369285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Investigator selected endocrine therapy will be taken in 28-day dosing cycles according to the approved prescribing information.~1 mg of anastrozole tablet by mouth once daily or~2.5 mg of letrozole tablet by mouth once daily or~25 mg of exemestane tablet by mouth once daily or~20 mg of tamoxifen tablet by mouth once daily or~500 mg of fulvestrant intramuscular injection on Study Day 1, 15, 29, and once every 28 days thereafter